Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 11, 2014, Pages

  Tramacere, Irene ^a   Del Giovane, Cinzia ^b   Salanti, Georgia ^c   D'Amico, Roberto ^b   Pacchetti, Ilaria ^a   Filippini, Graziella ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

COMPARATIVE EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 85041502509     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011381     Document Type: Review

References (73)

1. Aharoni R. Immunomodulation neuroprotection and remyelination. The fundamental therapeutic effects of glatiramer acetate: a critical review. Journal of Autoimmunity 2014 Jun 13 [Epub ahead of print]. [DOI: 10.1016/j.jaut.2014.05.005].
2. Association of British Neurologists 2005. Guidelines for the use of intravenous immunoglobulin in neurological diseases. www.theabn.org/documents/IVIg-Guidelines (accessed October 2013). [: OTHER].
3. Bennett J, Stüve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clinical Neuropharmacology 2009;32(3):121-32.
4. Caldwell D, Ades A, Higgins J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence as well. British Medical Journal 2005;331(7521):897-900.
5. Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003982.pub2].
6. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods 2012;3(2):161-76.
7. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in Stata. PLoS One 2013;8(10):e76654.
8. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clinical Immunology 2012;142:49-56.
9. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
11. Elovaara I, Apostolski S, van Doorn P, Gilhus N, Hietaharju A, Honkaniemi J, et al.EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. European Journal of Neurology 2008;15(9):893-908.
12. European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products European public assessment report: Tysabri. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000603/wapp/Post-authorisation/human_wapp_000166.jsp&mid=WC0b01ac058001d128 (accessed June 2014).
13. European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Gilenya. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002202/human_med_001433.jsp&mid=WC0b01ac058001d124 (accessed June 2014).
14. European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Aubagio. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002514/human_med_001645.jsp&mid=WC0b01ac058001d124 (accessed June 2014).
15. European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Lemtrada. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf (accessed June 2014).
16. European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Tecfidera. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdf (accessed June 2014).
17. European Medicines Agency. Refusal of the marketing authorisation for Nerventra (laquinimod). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002546/WC500160120.pdf (accessed June 2014).
18. European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products European public assessment report: Rebif. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000136/WC500122183.pdf (accessed June 2014).
19. European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products European public assessment report: Betaferon. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000081/human_med_000673.jsp&mid=WC0b01ac058001d124 (accessed June 2014).
20. U.S. Food, Drug Administration. Betaseron interferon beta-1b subcutaneous. Drug Approval Package - Licensing Action 1993. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103471s5063s5067s5079s5088s5120s5124s5136s5138lbl.pdf (accessed June 2014).
21. U.S. Food, Drug Administration. Glatiramer acetate (Capoxane) Product Approval Information - Licensing Action 1996. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (accessed June 2014).
22. U.S. Food, Drug Administration. Mitoxantrone (Novantrone) Product Approval Information - Licensing Action 2000. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=NOVANTRONE&CFID=17505855&CFTOKEN=fca8add70180e2b1-F1C49694-F504-892A-3B263F68EAFF59DC (accessed June 2014).
23. U.S. Food, Drug Administration. Interferon beta-1a (Rebif) Product Approval Information - Licensing Action 2002. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080737.htm (accessed June 2014).
24. U.S. Food, Drug Administration. Interferon beta-1a (Avonex) Product Approval Information - Licensing Action 2003. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103628s5021TOC.cfm (accessed June 2014).
25. U.S. Food, Drug Administration. Tysabri (Natalizumab) Product Approval Information 2004. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125104s000_Natalizumab.cfm (accessed June 2014).
26. U.S. Food, Drug Administration. FDA Approves Resumed Marketing of Tysabri Under a Special Distribution Program. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108662.htm (accessed June 2014).
27. U.S. Food, Drug Administration. Gilenya (Fingolimod) Product Approval Information 2010. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=022527&DrugName=GILENYA&ActiveIngred=FINGOLIMOD&SponsorApplicant=NOVARTIS&ProductMktStatus=1&goto=Search.DrugDetails (accessed June 2014).
28. U.S. Food, Drug Administration. Aubagio (Teriflunomide) Product Approval Information 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=202992&DrugName=AUBAGIO&ActiveIngred=TERIFLUNOMIDE&SponsorApplicant=SANOFI%20AVENTIS%20US&ProductMktStatus=1&goto=Search.DrugDetails (accessed June 2014).
29. U.S. Food, Drug Administration. Tecfidera (Dimethyl fumarate) Product Approval Information 2013. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204063&DrugName=TECFIDERA&ActiveIngred=DIMETHYL%20FUMARATE&SponsorApplicant=BIOGEN%20IDEC%20INC&ProductMktStatus=1&goto=Search.DrugDetails (accessed June 2014).
30. U.S Food, Drug Administration. Alemtuzumab (sBLA 103948). www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/peripheralandcentralnervoussystemdrugsadvisorycommittee/ucm374187.pdf (accessed June 2014).
31. Fox E. Mechanism of action of mitoxantrone. Neurology 2004;12:15-8.
32. Glenny A, Altman D, Song F, Sakarovitch C, Deeks J, D'Amico R, et al.Indirect comparisons of competing interventions. Health Technology Assessment 2005;9:1-34.
33. GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal 2004;(328):1490-4.
34. Brozek J, Oxman A, Schünemann H. GRADEpro Version 3.2 for Windows. Brozek J, Oxman A, Schünemann H, 2008.
35. Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
36. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research Synthesis Methods 2012;3:98-110.
37. Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, et al.Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 2012;(83):298-304.
38. Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, et al.A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. Journal of Clinical Pharmacology 2012;52:798-808.
39. Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, et al.Assessing changes in relapse rates in multiple sclerosis. Multiple Sclerosis 2010;16:1414-21.
40. Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Statistics in Medicine 2014;33(21):3639-54.
41. Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 2011;25:491-502.
42. Kremenchutzky M, Rice G, Baskerville J, Wingerchuk D, Ebers G. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006;(129):584-94.
43. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;(33):1444-52.
44. Lu G, Ades A. Assessing evidence inconsistency in mixed treatment comparisons. Journal of American Statistical Association 2006;101:447-59.
45. Lublin F, Reingold S. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
46. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al.Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-9.
47. McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001;50:121-7.
48. Nicholas R, Straube S, Schmidli H, Pfeiffer S, Friede T. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Multiple Sclerosis 2012;18:1290-6.
49. Oh J, Calabresi PA. Emerging injectable therapies for multiple sclerosis. Lancet Neurology 2013;12:1115-26.
50. Peters J, Sutton A, Jones D, Abrams K, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology 2008;61(10):991-6.
51. Polman C, Reingold S, Edan G, Filippi M, Hartung H, Kappos L, et al.Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Annals of Neurology 2005;58:840-6.
52. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al.Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology 2011;69:292-302.
53. Poser C, Paty D, Scheinberg L, McDonald W, Davis F, Ebers G, et al.New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13:227-31.
54. Salanti G, Marinho V, Higgins J. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. Journal of Clinical Epidemiology 2009;62:857-64.
55. Salanti G, Ades A, Ioannidis J. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64:163-71.
56. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS One 2014;9:e99682.
57. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 2014;85:67-75.
58. Schmied M, Duda PW, Krieger JI, Trollmo C, Hafler DA. In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis. Clinical Immunology 2003;106:163-74.
59. Schünemann H, Oxman A, Higgins J, Vist G, Glasziou P, Guyatt G. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
60. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, et al.Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-91.
61. Stangel M, Toyka K, Gold R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Archives of Neurology 1999;56(6):661-3.
62. Steinvorth SM, Röver C, Schneider S, Nicholas R, Straube S, Friede T. Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression. Multiple Sclerosis 2013;19:1580-6.
63. Stellmann JP, Neuhaus A, Herich L, Schippling S, Roeckel M, Daumer M, et al.Placebo cohorts in phase-3 MS treatment trials, predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PLoS One 2012;7(11):e50347. [DOI: 10.1371/journal.pone.0050347].
64. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al.CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. The Journal of Clinical Investigation 2003;111:1133-45. [PUBMED: 12697733].
65. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JPT. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Internal Journal Epidemiology 2012;41(3):818-27.
66. Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Experimental Neurology 2014 Apr 13 [Epub ahead of print].
67. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Internal Journal Epidemiology 2013;42(1):332-45.
68. White IR. Multivariate random-effects meta-regression: Updates to mvmeta. The STATA Journal 2011;11:255-70.
69. White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Research Synthesis Methods 2012;3(2):111-25.
70. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. Journal of Neuroinflammation 2010;7:30.
71. Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, et al.A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nature Medicine 2011;17:604-9.
72. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-6.
73. Yousry T, Major E, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al.Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. The New England Journal of Medicine 2006;354(9):924-33. [PUBMED: 16510746].